Mobile website
Archive > Volume 26 Issue 6 > 2019,26(6):617-622. DOI:10.3872/j.issn.1007-385X.2019.06.001 Prev Next
Expert Forum
New strategies for the treatment of neurotoxic side effects in CAR-T cell therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Chimeric antigen receptor modified T (CAR-T) cell therapy is one of the important methods of tumor immunotherapy. The targeting, killing, proliferation and persistence of CAR-T cells are significantly enhanced than that of conventional T cells. After continuous improvement and evolution, CAR-T cell treatment has achieved excellent progress in hematological tumors and has received extensive attention. However, neurotoxicity arising from the treatment, also known as CAR-T cell relevant encephalopathy syndrome (CRES), has affected its clinical application. Exploring the pathogenesis of CRES and high-risk factors, and finding appropriate strategies is therefore critical for the prevention and treatment of CRES. Here, we take CD19-CAR-T cell treatment as example to review the symptoms and pathogenesis of CRES, discuss high-risk factors as well as coping strategies, in an effort to provide a reference for clinical treatment.
Keywords:
Project Supported:
Project supported by the National Key Research and Development Program (No. 2018YFC1313400), the National Science and Technology Supporting Program (No.2015BAI12B12), the Joint Research Fund for Overseas Chinese, Hong Kong and Macao Scholars (No. 31729001), the National Natural Science Foundation of China (No.31570877, No.31570908), and the Key Research and Development Project of Science and Technology Department of Jiangsu Province (No.BE2018645)
Clc Number:
